



## Key Market Insights

More than 65 top selling biologics (revenues equal to or above USD 500 million in 2020) are currently available in the market

Majority (54%) of the aforementioned candidates are monoclonal antibodies, followed by hormones (19%) and enzymes (9%). Further, subcutaneous route (50%) emerged as the most preferred route of administration for such therapies, followed by the intravenous route (40%).

More than 50% the developers of top selling biologics are based in North America

The top [selling biologics market](#) is currently dominated by the presence of large companies (82%). Additionally, majority of such players were established before the year 2000.

Over 2,450 clinical trials registered for the evaluation of top selling biologics, till Q3 2020


Of the total, 1,892 trials were registered for the evaluation of products targeting oncological

disorders, followed by those investigating biologics intended for the treatment of metabolic disorders (122) and autoimmune disorders (98).

Around 250 biosimilars of top selling biologics are currently approved / under development. Close to 30% of the aforementioned candidates have already been approved. It is worth mentioning that over 100 biosimilars have received approval in Asia Pacific. Within this region, India and South Korea emerged as key hubs, having granted maximum approvals for biosimilars of top selling biologics (in terms of 2020 revenues).

Monoclonal antibodies are anticipated to capture over 75% of the market share by 2030

Over 40% of the market share is anticipated to be captured by Genentech / Roche and Merck by 2030. It is worth mentioning that as the patents of the currently marketed products have already / are expected to expire towards the end of the forecast period, the market is likely to reach maturity.



## Selling Biologics Market, 2021-2030 - Roots Analysis



To request a sample copy / brochure of this report, please visit this

<https://www.rootsanalysis.com/reports/top-selling-biologics-market/request-sample.html>

#### Key Questions Answered

- Which biologics are likely to attain the blockbuster status in the foreseen future?
- Who are the leading players engaged in the development of top selling biologics?
- Which key clinical conditions are presently targeted by top selling biologics?
- What are the historical global sales of top selling biologics?
- Which are the most commonly adopted product life cycle management strategies by players for their top selling products?
- What is the current annual treatment cost associated with top selling biologics?
- Which regions have emerged as the key hubs for conducting clinical studies focused on top selling biologics?
- How has the biosimilars landscape in this market evolved over the past few years?
- Which factors are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?

The USD 156 billion (by 2030) financial opportunity associated with the top selling biologics market has been analyzed across the following segments:

#### Type of Biologic

- Monoclonal Antibodies
- Hormones
- Fusion Proteins
- Enzymes
- Interferons
- Antibody Fragments
- Gene Therapies
- Vaccines

#### Key Developers

- Genentech / Roche
- AbbVie
- Janssen Biotech / Johnson & Johnson
- Amgen
- Eli Lilly
- Bristol Myers Squibb
- Sanofi
- Novo Nordisk
- Regeneron

For additional details, please visit

<https://www.rootsanalysis.com/reports/top-selling-biologics-market.html> or email

sales@rootsanalysis.com

You may also be interested in the following titles:

1. Novel T-Cell Immunotherapies Market, 2021-2030
2. CAR-T-based Therapies Market, 2021-2030
3. Non-Hormonal Therapies Market, 2021-2030
4. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
5. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Gaurav Chaudhary

Roots Analysis

+1 415-800-3415

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/553556227>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.